CORDIS - Forschungsergebnisse der EU
CORDIS

Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases

Projektbeschreibung

Forschung zu digitalen Endpunkten von Schlaf und Müdigkeit

Neurodegenerative Krankheiten und immunvermittelte entzündliche Erkrankungen gehen oft mit Müdigkeit und Schlafstörungen einher. Beide Symptome verschlechtern die Lebensqualität und verursachen beträchtliche Kosten im Gesundheitswesen. Bislang erfolgt eine Bewertung jedoch nur auf Basis einer schriftlichen Selbstauskunft, was die Aussagefähigkeit deutlich einschränkt, keine zuverlässigen Schlussfolgerungen zulässt und auch therapeutische Erfolge nicht berücksichtigt. Das EU-finanzierte Projekt IDEA-FAST wird neue digitale Endpunkte für Müdigkeit und Schlafstörungen festlegen und objektivere und zuverlässigere Kriterien zur Bewertung von Schweregrad und Auswirkungen der Symptome entwickeln. Ziel des Projekts ist es, die Schlüsselmechanismen dieser beiden Störungen zu verstehen und klinische Studien aussagefähiger zu gestalten, um neue und kostengünstigere Therapien zu entwickeln.

Ziel

Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-mediated inflammatory diseases (IMID). These symptoms are major predictors of poor quality of life and increased healthcare cost. Current questionnaire-based approaches to measure these symptoms have key limitations preventing them from being used as reliable endpoints in clinical trials to evaluate the effect of therapies.

IDEA-FAST aims to address these issues by identifying novel digital endpoints for fatigue and sleep disturbances that will provide more objective, sensitive and reliable measures of the severity and impact of these symptoms in ecological settings. Such digital endpoints will not only help to gain insight into the underpinning mechanisms of fatigue and sleep disturbances, but will also vastly improve the efficiency of clinical trials, ultimately reducing the time and cost to bring new therapies to patients.

To identify these digital endpoints, we will follow the recommendations of the Clinical Trials Transformation Initiative (CTTI). We will identify the characteristics that fatigue and sleep disturbances will have impact, then select the digital measures (endpoints) to quantify them, followed by choosing the appropriate digital device/technology accordingly. We will then perform a pilot study to prioritise a few of these candidate digital endpoints for validation. We will test the performance of these digital endpoints in two NDD and four IMID in a large longitudinal study during which extensive relevant clinical data will be collected. If these digital endpoints were validated, we will seek support from EMA/FDA for their qualification. Patient users’ perspective, ethical, data privacy, legal and other regulatory issues will be taken into consideration in all aspects of our proposal.

The resultant digital biobank from the longitudinal study will become an invaluable resource for future exploitation.

Koordinator

UNIVERSITY OF NEWCASTLE UPON TYNE
Netto-EU-Beitrag
€ 4 644 337,05
Adresse
KINGS GATE
NE1 7RU Newcastle Upon Tyne
Vereinigtes Königreich

Auf der Karte ansehen

Region
North East (England) Northumberland and Tyne and Wear Tyneside
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 5 371 912,05

Beteiligte (59)